Milsaperidone

Milsaperidone
Clinical data
Trade namesBysanti
Other namesVHX896, VHX-896
AHFS/Drugs.comMonograph
MedlinePlusa626033
License data
Routes of
administration
Oral
Drug classAtypical antipsychotic
ATC code
  • None
Legal status
Legal status
Identifiers
  • (1S)-1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC24H29FN2O4
Molar mass428.504 g·mol−1
3D model (JSmol)
  • C[C@@H](C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC)O
  • InChI=1S/C24H29FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-17,28H,3,8-13H2,1-2H3/t16-/m0/s1
  • Key:SBKZGLWZGZQVHA-INIZCTEOSA-N

Milsaperidone, sold under the brand name Bysanti, is a medication used for the treatment of schizophrenia and bipolar disorder. It is an atypical antipsychotic. It is a prodrug of iloperidone and acts as a dopamine D2 receptor and serotonin 5-HT2A receptor antagonist, among other actions. Milsaperidone was developed by Vanda Pharmaceuticals.

Milsaperidone was approved for medical use in the United States in February 2026.

Medical uses

Milsaperidone is indicated for the treatment of schizophrenia; and for the acute treatment of manic or mixed episodes associated with bipolar I disorder.

Society and culture

Milsaperidone was approved for medical use in the United States in February 2026.

Names

Milsaperidone is the international nonproprietary name.

Milsaperidone is sold under the brand name Bysanti.

Research

Milsaperidone is in phase III clinical trials for treatment of major depressive disorder.